Apigenin, chrysin, and luteolin selectively inhibit chymotrypsin-like and trypsin-like proteasome catalytic activities in tumor cells

Planta Medica

Volumn 76, Issue 2, 2010, Pages 128-132

  Wu, Yi Xin ^a   Fang, Xin ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Flavonoids; Inhibitors; Proteasomes

Indexed keywords

APIGENIN; CHRYSIN; CHYMOTRYPSIN; FLAVONOID; LUTEOLIN; PROTEASOME; PROTEASOME INHIBITOR; TRYPSIN; UBIQUITIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CATALYSIS; CELL CYCLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APIGENIN; CELL LINE, TUMOR; CHYMOTRYPSIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HUMANS; HYDROLYSIS; LUTEOLIN; NEOPLASMS; PEPTIDES; PLANT EXTRACTS; PROTEASOME ENDOPEPTIDASE COMPLEX; TRYPSIN; UBIQUITIN;

EID: 74349115989     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1186004     Document Type: Article

References (18)

1. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998 17 7151-7160
2. Li B, Dou Q P. Bax degradation by the ubiquitin-proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000 97 3850-3855
3. Myung J, Kim K B., Crews C M. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001 21 245-273
4. Naujokat C, Hoffman S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 2002 82 956-980
5. Groll M, Heinemeyer W, Jager S, Ullrich T, Bochtler M, Wolf D H., Huber R. The catalytic sites of 20S proteasome and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci USA 1999 96 10976-10983
6. Ciechanover A, Orian A, Schwartz A L. Ubiquitin-mediated proteolysis; biological reglation via destruction. Bioessays 2000 22 442-451
7. Crawford L J., Walker B, Ovaa H, Chauhan D, Anderson K C., Morris T C., Irvine A F. Comparative selectivity and specificity of the proteasome inhibitors bzlllcocho, ps-341, and Mg-132. Cancer Res 2006 66 6379-6386
8. Kazi A, Daniel K G., Smith D M., Kumar N B., Dou Q P. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003 66 965-976
9. Nam S, Smith D M., Dou Q P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001 276 13322-13330
10. Ross J A., Kasum C M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002 22 19-34
11. Feng X, Zhang L, Zhu H. Comparative anticancer and antioxidant activities of different ingredients of Ginkgo biloba extract (ECB761). Planta Med 2009 75 792-796
12. Seelinger G, Merfort I, Schempp C M. Anti-oxidant, anti-inflammadtory and anti-allergic activities of luteolin. Planta Med 2008 14 1667-1677
13. Neuhouser M L. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer 2004 50 1-7
14. Chen D, Chen M S., Cui Q C., Yang H, Dou Q P. Structure-proteasome- inhibitory activity relationships of dietary flavonoids in human cancer cells. Frontiers Biosci 2007 12 1935-1945
15. Chen D, Daniel K G., Chen M S., Kuhn D J., Landis-Piwowar K R., Dou Q P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 2005 69 1421-1432
16. Landis-Piwowar K R., Milacic V, Chen D, Yang H, Zhao Y, Chan T H., Yan B, Dou Q P. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat 2006 9 263-273
17. Kane R C., Brose P F., Frarell A T., Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncology 2003 8 508-513
18. Richardson P G., Barlogie B, Berenson J, Singhai S, Jagannath S, Irwin D, Rajkumar S V., Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski R Z., Kuter D, Limentani S A., Lee S, Hideshima T, Esseltine D L., Kauffman M, Adams J, Schenkein D P., Anderson K C. A phase 2 study of bortezomib in relapsed, refractory myloma. N Eng J Med 2003 348 2609-2617